Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, has appointed Ibs Mahmood as Chief Executive Officer (CEO). Mahmood succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction. Mahmood brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 mill...